Mutations of the Ki-ras oncogene in endometrial carcinoma
References (23)
- et al.
Genetic and cellular basis of multistep carcinogenesis
Pharmacol Ther
(1990) - et al.
Hereditary nonpolyposis colorectal cancer (Lynch syndromes I & II). Genetics, pathology, natural history, and cancer control. Part I
Cancer Genet Cytogenet
(1991) - et al.
Second primary malignancy in endometrial carcinoma patients
Gynecol Oncol
(1985) - et al.
Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease
Am J Obstet Gynecol
(1991) - et al.
The cytokine CSF-1 (M-CSF) expressed by endometrial carcinomas in vivo and in vitro, may also be a circulating tumor marker of neoplastic disease activity in endometrial carcinoma patients
Int J Radiat Oncol Biol Phys
(1990) - et al.
Point mutations at codon 12 of c-K-ras in human endometrial carcinomas
Cancer Lett
(1990) - et al.
The epidemiology of endometrial cancer
Gynecol Oncol
(1991) - et al.
Purification of DNA from formaldehyde fixed and paraffin embedded human tissue
Biochem Biophys Res Commun
(1985) - et al.
Endometrial carcinoma: two diseases?
Cancer Detect Prev
(1987) - et al.
Endometrial carcinoma
Familial cancer aggregation in cases of adenocarcinoma corporis uteri
Acta Obstet Gynecol Scand
Cited by (76)
Molecular Genetics of Endometrial Cancers
2004, Gynecologic Cancer: Controversies in ManagementK-ras exon 2 point mutations in human endometrial cancer
2001, Cancer LettersProspects for applying genotypic selection of somatic oncomutation to chemical risk assessment
2001, Mutation Research - Reviews in Mutation ResearchMolecular pathology of endometrial hyperplasia and carcinoma
2001, Human PathologyCitation Excerpt :Results from our group and others suggest that, again, aberrant promoter methylation might be the cause of PTEN suppression in some cases of EC.73,74 k-RAS mutations have been identified in 40% to 50% of colon carcinomas, but in approximately 10% to 30% of ECs.18-28 Although some investigators have failed to show a correlation between k-RAS mutations and stage, grade, depth of invasion, age, or clinical outcome in EC,75 others have described associations between k-RAS mutations and the presence of coexistent endometrial hyperplasia,23 lymph node metastases, and clinical outcome in postmenopausal patients over 60 years of age.24
Expression of fos and jun proto-oncogenes in benign versus malignant human uterine tissue
2000, Gynecologic Oncology
- a
From the Laboratory of Reproductive and Developmental Toxicology, National Institutes of Health, Research Triangle Park
- b
Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park
- c
Department of Pathology, University of North Carolina School of Medicine, Chapel Hill
- d
Department of Obstetrics and Gynecology, Duke University Medical Center, Durham.